Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kotra Industries BhdXKLS:0002 +1.35%83 EV-to-EBITDA is 8.63 as of Aug. 02, 2026, which is at its 10-year median of 8.63. GuruFocus rates XKLS:0002 with a GF Score™ of 83/100 and a GF Value™ of RM4.35 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 746 Drug Manufacturers companies, Kotra Industries Bhd ranks better than 68.23% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kotra Industries Bhd's enterprise value is RM536.3 Mil.
Kotra Industries Bhd's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was RM62.1 Mil. Therefore, Kotra Industries Bhd's EV-to-EBITDA for today is 8.63.
The historical rank and industry rank for Kotra Industries Bhd's EV-to-EBITDA or its related term are showing as below:
XKLS:0002'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.16 Med: 8.63 Max: 12.1
Current: 8.63
During the past 13 years, the highest EV-to-EBITDA of Kotra Industries Bhd was 12.10. The lowest was 6.16. And the median was 8.63.
XKLS:0002's EV-to-EBITDA is ranked better than 68.23% of 746
companies
in the Drug Manufacturers industry
Industry Median: 12.995
vs XKLS:0002: 8.63
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Kotra Industries Bhd (XKLS:0002) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kotra Industries Bhd's PE Ratio (TTM) for today is calculated as:
Kotra Industries Bhd's share price for today is RM3.75.
Kotra Industries Bhd's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0.257.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Kotra Industries Bhd's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0002 vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kotra Industries Bhd's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kotra Industries Bhd EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kotra Industries Bhd's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kotra Industries Bhd's EV-to-EBITDA falls into.
Kotra Industries Bhd's current Enterprise Value is RM536.3 Mil.
Kotra Industries Bhd's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM62.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kotra Industries Bhd (XKLS:0002) has a EV-to-EBITDA of 8.63 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kotra Industries Bhd. This is near median its historical median of 8.63. Over the past decade, Kotra Industries Bhd's EV-to-EBITDA has ranged from 6.16 to 12.10. According to the industry distribution chart, Kotra Industries Bhd ranks #237 out of 746 companies in the Drug Manufacturers industry, placing it in the top 31.8%.
Is Kotra Industries Bhd's EV-to-EBITDA too high?
Kotra Industries Bhd's current EV-to-EBITDA of 8.63 is near median its 10-year median of 8.63. Over the past 10 years, this metric has ranged from a low of 6.16 to a high of 12.10. The Drug Manufacturers industry median EV-to-EBITDA is 13.00. Kotra Industries Bhd's value of 8.63 is 33.6% below this industry median. Based on the distribution chart, Kotra Industries Bhd ranks #237 out of 746 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kotra Industries Bhd has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kotra Industries Bhd's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kotra Industries Bhd ranks #237 out of 746 companies for EV-to-EBITDA. This puts Kotra Industries Bhd in the upper half of its industry. The industry median EV-to-EBITDA is 13.00. Kotra Industries Bhd's value of 8.63 is 33.6% below this benchmark. Historically, Kotra Industries Bhd's own EV-to-EBITDA has ranged from 6.16 to 12.10 over the past decade. While the company's 10-year median is 8.63 vs. the industry median of 13.00, Kotra Industries Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.00, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kotra Industries Bhd's current EV-to-EBITDA of 8.63 is 33.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kotra Industries Bhd. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kotra Industries Bhd's current EV-to-EBITDA is 8.63, which is near median its own 10-year median of 8.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kotra Industries Bhd stock overvalued right now?
Based on GuruFocus' analysis, Kotra Industries Bhd (XKLS:0002) is currently considered Modestly Undervalued. The stock's GF Value™ is RM4.35, compared to a current price of RM3.75 — trading 13.8% below its estimated fair value. The current EV-to-EBITDA is 8.63, which is near median its 10-year median of 8.63 and 33.6% below the Drug Manufacturers industry median of 13.00. Kotra Industries Bhd's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Kotra Industries Bhd (XKLS:0002), the current EV-to-EBITDA is 8.63 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kotra Industries Bhd (XKLS:0002) Overvalued in 2026?
Based on GuruFocus' analysis, Kotra Industries Bhd stock appears to be undervalued.
The current stock price of RM3.75 is trading 13.8% below its estimated GF Value™ of RM4.35.
GuruFocus considers Kotra Industries Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:0002:
EV-to-EBITDA: 8.63 (near median its 10-year median of 8.63)
GF Value™: RM4.35 vs. price of RM3.75 (13.8% below fair value)
Industry Position: 33.6% below the Drug Manufacturers median (#237 of 746)
No single metric tells the full story. See the XKLS:0002 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kotra Industries Bhd is a Malaysian pharmaceutical company engaged in the development, manufacturing, and supply of pharmaceutical and healthcare products supporting all life stages. Its portfolio includes life-saving medicines, OTC supplements, and nutrition products. The Group markets three core brands: Appeton, offering health supplements and nutrition across all age groups; Vaxcel, providing injectable medicines for infectious diseases, kidney care, and gastroenterology; and Axcel, specializing in oral and topical medicines for paediatrics, dermatology, and infectious diseases. The company operates in Malaysia and overseas, with the majority of revenue derived from Malaysia.
83GF Score
Get the complete analysis for XKLS:0002
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0002 has been successfully added to your 
